CalciMedica Analyst Price Targets

Wall Street analyst price targets and consensus rating for CalciMedica (CALC).

Price Target Range — 9 Quarters

Analyst Consensus — 5 Analysts

4Buy

1Hold

Consensus RatingBuy# Analysts5Avg. Consensus PT$74Upside to Avg. PT+5965.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 20, 2026	Guggenheim	Vamil Divan	Initiate	Buy	$45
Mar 5, 2026	Oppenheimer	Leland Gershell	PT Cut	Outperform	$100→$50
Jan 29, 2026	HC Wainwright & Co.	Joseph Pantginis	Downgrade	Buy→Neutral	—
May 15, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$80
Apr 1, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$80
Mar 4, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$80
Dec 17, 2024	LUCID CAPITAL MARKETS	Dev Prasad	Initiate	Buy	$65
Nov 14, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$80
Nov 4, 2024	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$100→$80
Aug 13, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$100
Jul 10, 2024	Oppenheimer	Leland Gershell	PT Raise	Outperform	$70→$100
Jul 9, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$100
Jun 27, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$100
May 14, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$100
Apr 1, 2024	Oppenheimer	Leland Gershell	Maintained	Outperform	$70
Apr 1, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$100
Mar 13, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$100
Feb 16, 2024	JonesTrading	Catherine Novack	Initiate	Buy	$110
Feb 13, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$100
Jan 29, 2024	HC Wainwright & Co.	Joseph Pantginis	Initiate	Buy	$100

Analyst Ratings News

PRO
Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9

Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on CalciMedica, Lowers Price Target to $10

Oppenheimer analyst Leland Gershell maintains CalciMedica (NASDAQ:CALC) with a Outperform and lowers the price target from $20 to $10.

Benzinga Newsdesk

This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades CalciMedica to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades CalciMedica (NASDAQ:CALC) from Buy to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $16 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $16 price target.

Benzinga Newsdesk

CalciMedica Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

CalciMedica Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9

PRO
Oppenheimer Maintains Outperform on CalciMedica, Lowers Price Target to $10

This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

PRO
HC Wainwright & Co. Downgrades CalciMedica to Neutral

PRO
HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

People Also Watch

People Also Watch

CalciMedica Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

CalciMedica Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9

PROOppenheimer Maintains Outperform on CalciMedica, Lowers Price Target to $10

This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

PROHC Wainwright & Co. Downgrades CalciMedica to Neutral

PROHC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

PROHC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

People Also Watch

People Also Watch

PRO
Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9

PRO
Oppenheimer Maintains Outperform on CalciMedica, Lowers Price Target to $10

PRO
HC Wainwright & Co. Downgrades CalciMedica to Neutral

PRO
HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target